Working… Menu

Fat Cell Size and Overfeeding and Etopic Study (EAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01672632
Recruitment Status : Completed
First Posted : August 27, 2012
Last Update Posted : May 3, 2021
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Eric Ravussin, Pennington Biomedical Research Center

Brief Summary:
It has been shown that large fat cells are associated with more risks for insulin resistance and more cardiovascular risk factors such as high cholesterol or triglycerides.

Condition or disease Intervention/treatment Phase
Over Eating Other: Overfeeding Not Applicable

Detailed Description:
This study will look at fat cell size and how it affects fat deposition, insulin resistance and muscle oxidative capacity. A comparison will be made with the differences between participants with larger versus smaller fat cells in insulin resistance and blood levels of lipids. The study will also determine if characteristics of fat cells and muscle can predict the development of weight gain-induced insulin resistance.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Fat Cell Size and Overfeeding and Etopic Study
Actual Study Start Date : May 2008
Actual Primary Completion Date : February 2012
Actual Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: Overfeeding
We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
Other: Overfeeding
We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.

Primary Outcome Measures :
  1. Determine the effect of 8-weeks 40% high fat overfeeding in 40 healthy, young adults on adipose and skeletal muscle characteristics, ectopic fat accumulation, insulin sensitivity, and metabolic flexibility. [ Time Frame: 10 months ]
    This study will investigate how fat cell size (independent of total fat mass) affects metabolic outcomes of overfeeding, including changes in fat deposition, insulin sensitivity and muscle oxidative capacity. It has been shown that large fat cells relative to fat mass are associated with higher risks for insulin resistance and type 2 diabetes.

Secondary Outcome Measures :
  1. Fat Deposition [ Time Frame: 10 Months ]
    Viewing of adipose tissue or body fat and skeletal muscle characteristics over a period.

  2. Insulin Sensitivity [ Time Frame: 10 months ]
    Measure and monitor the natural hormone insulin becomes less effective at lowering blood sugars. The resulting increase in blood glucose may raise levels outside the normal range and cause adverse heealth effects, depending on dietary conditions or sensitivity of cells to insulin.

  3. Muscle Oxidative Capacity [ Time Frame: 10 Months ]
    A measure of a muscle's maximal capacity to use oxygen in microliters of oxygen consumed per gram of muscle per hour.

  4. Circadian Blood Pressure variability [ Time Frame: 10 Months ]
    Blood pressure and heart rate measurement: An automatic BP monitoring device (Mortara® Ambulo 2400) for ambulatory use was attached to a BP cuff to obtain blood pressure (BP) and heart rate (HR) readings at 30-min intervals during the day (6:30 AM to 9:30 PM) and 60-min intervals at night (10 PM to 6 AM) while the participants went about their activities. Data were downloaded into the database at the end of the 7-day recording span for a chronobiological analysis. This was done at baseline, post-overfeeding and at 3 months.

  5. Resting Endothelial function testing [ Time Frame: 10 Months ]
    Endothelial function testing: Assessment of resting endothelial function was done with the participant in a fasting state, after having avoided stimulants (caffeine, tobacco, alcohol, exercise) for 12 hours, at the same fixed clock hour (range 8-10 AM), using the EndoPAT 2000 device manufactured by ITAMAR Medical®.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Your Body Mass Index (height to weight ratio) is 22.5 to 32.5 (inclusive).
  • You are 18-40 years of age.
  • You are willing to enroll in an 8 week overfeeding study causing a 5-8 % weight gain.
  • You are willing to eat all your meals from Pennington and only meals from Pennington for approximately 10 weeks total, even when you are full. Prior to overfeeding 2 Meals per day will be served at Pennington with lunch packed for at least 7 days. After that time participants will receive and eat all (overfeeding) meals at PBRC for 8 weeks. Post-overfeeding will consists of weight-maintenance diet for 1 week. All meals will be monitored at Pennington.
  • You are willing to maintain the same level of exercise after enrollment in the study throughout the length of the study.
  • You are willing to complete nutritional and activity questionnaires.

Exclusion Criteria:

  • You weight > 300 lbs
  • You have a history of cardiovascular disease or diabetes.
  • You have a fasting blood glucose > 110 mg/dL.
  • You have an average screening blood pressure > 140/90.
  • You have liver disease.
  • You have thyroid disease.
  • Have Acid Reflux
  • Had cancer in the last 5 years (Some skin cancers OK)
  • Have HIV
  • Have had an Eating Disorders
  • You are pregnant or breastfeeding.
  • You have gained or lost more than 3kg in the last 3 months
  • You require chronic use of medications including diuretics, steroids and adrenergic-stimulating agents.
  • You or a member of your family has a history of blood clots (deep vein thrombosis or pulmonary embolism)
  • You have poor circulation, history of bypass operation in your legs, blood coagulation disorders, diagnosed peripheral arterial or vascular disease, cramping pain in your leg muscle during exercise or nerve damage to your legs
  • You have varicose veins (per discretion of MD or NP)
  • You have had previous GI surgery, obstructive disease of the GI tract, hyper motility disorder or a history of problems of impairment of the gag reflex.
  • You have emotional problems such as clinical depression or other diagnosed psychological conditions.
  • You are claustrophobic.
  • You have metal objects in your body such as implanted rods or surgical clips or magnetic objects that are incompatible with the MRI/MRS.
  • You smoke or use tobacco products

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01672632

Layout table for location information
United States, Louisiana
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States, 70808
Sponsors and Collaborators
Pennington Biomedical Research Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Layout table for investigator information
Principal Investigator: Eric Ravussin, PhD Pennington Biomedical Research Center
Principal Investigator: Alok Gupta, MD Pennington Biomedial Research Center
Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Eric Ravussin, Principal Investigator, Pennington Biomedical Research Center Identifier: NCT01672632    
Other Study ID Numbers: PBRC 26040
5R01DK060412 ( U.S. NIH Grant/Contract )
First Posted: August 27, 2012    Key Record Dates
Last Update Posted: May 3, 2021
Last Verified: April 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive